Literature DB >> 8916082

Septal vasopressin modulates anxiety-related behaviour in rats.

G Liebsch1, C T Wotjak, R Landgraf, M Engelmann.   

Abstract

Arginine vasopressin (AVP) or its V1 receptor antagonist d(CH2)5Tyr(Me)AVP was administered directly into the septal brain area of adult male rats by means of inverse microdialysis. Immediately after a 30-min dialysis period, during which either approximately 0.25 ng AVP or 5 ng of the V1 antagonist were delivered into the brain tissue, anxiety-related behaviour of the animals was measured on an elevated plus-maze apparatus. While synthetic AVP failed to alter plus-maze behaviour compared to vehicle-treated controls, animals treated with the V1 receptor antagonist made more entries into (P < 0.01) and spent more time on the open arms (P < 0.05), indicating reduced anxiety. Since administration of neither AVP nor the V1 antagonist significantly influenced general locomotor activity of the rats on the plus-maze and in an open field, these data point towards a critical involvement of intraseptally released AVP in the emotional evaluation of novel situations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916082

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  39 in total

1.  Variation in maternal and anxiety-like behavior associated with discrete patterns of oxytocin and vasopressin 1a receptor density in the lateral septum.

Authors:  J P Curley; C L Jensen; B Franks; F A Champagne
Journal:  Horm Behav       Date:  2012-01-28       Impact factor: 3.587

Review 2.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

3.  A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

Authors:  S V Koroleva; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2006-02

4.  Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.

Authors:  C J Bleickardt; D E Mullins; C P Macsweeney; B J Werner; A J Pond; M F Guzzi; F D C Martin; G B Varty; R A Hodgson
Journal:  Psychopharmacology (Berl)       Date:  2008-10-16       Impact factor: 4.530

5.  Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and women.

Authors:  Xu Chen; Patrick D Hackett; Ashley C DeMarco; Chunliang Feng; Sabrina Stair; Ebrahim Haroon; Beate Ditzen; Giuseppe Pagnoni; James K Rilling
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

6.  Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling.

Authors:  L Torner; N Toschi; A Pohlinger; R Landgraf; I D Neumann
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

Review 7.  Evolving nonapeptide mechanisms of gregariousness and social diversity in birds.

Authors:  James L Goodson; Aubrey M Kelly; Marcy A Kingsbury
Journal:  Horm Behav       Date:  2012-01-13       Impact factor: 3.587

Review 8.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

9.  Social enrichment during postnatal development induces transgenerational effects on emotional and reproductive behavior in mice.

Authors:  James P Curley; Stephanie Davidson; Patrick Bateson; Frances A Champagne
Journal:  Front Behav Neurosci       Date:  2009-09-15       Impact factor: 3.558

10.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.